Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report
Open Access
- 8 May 2019
- journal article
- research article
- Published by Taylor & Francis in Lung Cancer Management
- Vol. 8 (2) , LMT10
Abstract
A 57-year-old man presented with swelling and pain in the lower limbs, inability to walk and increasing dyspnea for 2 days. Because of refractory stage IV non-small-cell lung cancer, pembrolizumab ...Keywords
This publication has 10 references indexed in Scilit:
- Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literatureCancer, 2017
- Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragmAnnals of Oncology, 2016
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1The Oncologist, 2016
- Pembrolizumab-induced necrotic myositis in a patient with metastatic melanomaAnnals of Oncology, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- New modalities of cancer treatment for NSCLC: focus on immunotherapyCancer Management and Research, 2014